Antiviral therapy: Old and current issues

International Journal of Antimicrobial Agents

Volumn 40, Issue 2, 2012, Pages 95-102

  Antonelli, Guido ^a   Turriziani, Ombretta ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiviral activity; Antiviral agents; Antiviral drugs; Antiviral therapy; HIV; Virus

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ABACAVIR; ACICLOVIR; AMANTADINE; AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; CIDOFOVIR; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; INTEGRASE INHIBITOR; LAMIVUDINE; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PALIVIZUMAB; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RIMANTADINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFLUENZA A; NONHUMAN; NUCLEIC ACID SYNTHESIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN TARGETING; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; VIREMIA; VIRUS DNA CELL DNA INTERACTION; VIRUS INFECTION; VIRUS RESISTANCE; VIRUS UNCOATING;

EID: 84864277575     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.04.005     Document Type: Short Survey

References (84)

1. G.B. Elion, P.A. Furman, J.A. Fyfe, P. de Miranda, L. Beauchamp, and H.J. Schaeffer Selectivity of action of an antiherpetic agent, 9-(2- hydroxyethoxymethyl) guanine Proc Natl Acad Sci USA 74 1977 5716 5720
2. J.A. Fyfe, P.M. Keller, P.A. Furman, R.L. Miller, and G.B. Elion Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine J Biol Chem 253 1978 8721 8727
3. C.A. Alford Jr., and R.J. Whitley Treatment of infections due to herpesvirus in humans: a critical review of the state of the art J Infect Dis 133 Suppl. 1976 A101 A108
4. H.H. Balfour Jr. Antiviral drugs N Engl J Med 340 1999 1255 1268
5. S. Vella HIV therapy advances. Update on a proteinase inhibitor AIDS 8 Suppl. 3 1994 S25 S29
6. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, and D.J. Aschman Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 1998 853 860
7. E. De Clercq The design of drugs for HIV and HCV Nat Rev Drug Discov 6 2007 1001 1018
8. E. De Clercq A 40-year journey in search of selective antiviral chemotherapy Annu Rev Pharmacol Toxicol 51 2011 1 24
9. E.C. Borden, G.C. Sen, G. Uze, R.H. Silverman, R.M. Ransohoff, and G.R. Foster Interferons at age 50: past, current and future impact on biomedicine Nat Rev Drug Discov 6 2007 975 990
10. G. Antonelli Biological basis for a proper clinical application of α interferons New Microbiol 31 2008 305 318
11. J.A. Esté, and A. Telenti HIV entry inhibitors Lancet 370 2007 81 88
12. J.C. Tilton, and R.W. Doms Entry inhibitors in the treatment of HIV-1 infection Antiviral Res 85 2010 91 100
13. V. Soriano, C.F. Perno, R. Kaiser, V. Calvez, J.M. Gatell, and G. di Perri When and how to use maraviroc in HIV-infected patients AIDS 23 2009 2377 2385
14. R.C. Welliver Pharmacotherapy of respiratory syncytial virus infection Curr Opin Pharmacol 10 2010 289 293
15. J. Hu, and J.L. Robinson Treatment of respiratory syncytial virus with palivizumab: a systematic review World J Pediatr 6 2010 296 300
16. M. Lanari, M. Silvestri, and G.A. Rossi Palivizumab prophylaxis in 'late preterm' newborns J Matern Fetal Neonatal Med 23 Suppl. 3 2010 53 55
17. T. Matthews, M. Salgo, M. Greenberg, J. Chung, R. DeMasi, and D. Bolognesi Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes Nat Rev Drug Discov 3 2004 215 225
18. M. Perros CCR5 antagonists for the treatment of HIV infection and AIDS Adv Antiviral Drug Design 5 2007 185 212
19. L.J. Scott, and H.M. Lamb Palivizumab Drugs 58 1999 305 311
20. W.L. Davies, R.R. Grunert, F. Haff, J.W. McGahen, E.M. Neumayer, and M. Paulshock Antiviral activity of 1-adamantanamine (amantadine) Science 144 1964 862 863
21. L.H. Pinto, L.J. Holsinger, and R.A. Lamb Influenza virus M2 protein has ion channel activity Cell 69 1992 517 528
22. K. Martin, and A. Helenius Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import Cell 67 1991 117 130
23. A.J. Hay, M.C. Zambon, A.J. Wolstenholme, J.J. Skehel, and M.H. Smith Molecular basis of resistance of influenza A viruses to amantadine J Antimicrob Chemother 18 Suppl. B 1986 19 29
24. C.H. Tsai, P.Y. Lee, V. Stollar, and M.L. Li Antiviral therapy targeting viral polymerase Curr Pharm Des 12 2006 1339 1355
25. S.E. Straus, H.E. Takiff, M. Seidlin, S. Bachrach, L. Lininger, and J.J. DiGiovanna Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir N Engl J Med 310 1984 1545 1550
26. J.M. Douglas, C. Critchlow, J. Benedetti, G.J. Mertz, J.D. Connor, and M.A. Hintz A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex 3 virus infection N Engl J Med 310 1984 1551 1556
27. M.A. Fischl, D.D. Richman, M.H. Grieco, M.S. Gottlieb, P.A. Volberding, and O.L. Laskin The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial N Engl J Med 317 1987 185 191
28. J.L. Dienstag Benefits and risks of nucleoside analog therapy for hepatitis B Hepatology 49 5 Suppl. 2009 S112 S121
29. D.M. Coen, and P.A. Schaffer Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets Nat Rev Drug Discov 2 2003 278 288
30. M. von Kleist, P. Metzner, R. Marquet, and C. Schütte HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection PLoS Comput Biol 8 2012 e1002359
31. G.B. Elion Acyclovir: discovery, mechanism of action and selectivity J Med Virol Suppl. 1 1993 2 6
32. W.H. Miller, and R.L. Miller Phosphorylation of acyclovir diphosphate by cellular enzymes Biochem Pharmacol 31 1982 3879 3884
33. G.R. Painter, M.R. Almond, S. Mao, and D.C. Liotta Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase Curr Top Med Chem 4 2004 1035 1044
34. E. De Clercq, and A. Hol Acyclic nucleoside phosphonates: a key class of antiviral drugs Nat Rev Drug Discov 4 2005 928 940
35. E. De Clercq The history of antiretrovirals: key discoveries over the past 25 years Rev Med Virol 19 2009 287 299
36. M.P. de Béthune Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009) Antiviral Res 85 2010 75 90
37. L.A. Kohlstaedt, J. Wang, and T.A. Steitz Crystal structure at 3.5 resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science 256 1992 1783 1790
38. J. Adams, N. Patel, N. Mankaryous, M. Tadros, and C.D. Miller Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents Ann Pharmacother 44 2010 157 165
39. D.S. Schiller, and M. Youssef-Bessler Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV Clin Ther 31 2009 692 704
40. Z. Hong, and C.E. Cameron Pleiotropic mechanisms of ribavirin antiviral activities Prog Drug Res 59 2002 41 69
41. N.J. Stevenson, A.G. Murphy, N.M. Bourke, C.A. Keogh, J.E. Hegarty, and C. O'Farrelly Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV PLoS One 6 2011 e27866
42. D.J. Hazuda, P. Felock, M. Witmer, A. Wolfe, K. Stillmock, and J.A. Grobler Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells Science 287 2000 646 650
43. Y. Pommier, A.A. Johnson, and C. Marchand Integrase inhibitors to treat HIV/AIDS Nat Rev Drug Discov 4 2005 236 248
44. B. Grinsztejn, B.Y. Nguyen, C. Katlama, J.M. Gatell, A. Lazzarin, and D. Vittecoq Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial Lancet 369 2007 1261 1269
45. K. Shimura, and E.N. Kodama Elvitegravir: a new HIV integrase inhibitor Antivir Chem Chemother 20 2009 79 85
46. J.J. Eron Jr. HIV-1 protease inhibitors Clin Infect Dis 30 Suppl. 2 2000 S160 S170
47. B. Luna, and M.U. Townsend Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance Clin Ther 29 2007 2309 2318
48. C. McCoy Darunavir: a nonpeptidic antiretroviral protease inhibitor Clin Ther 29 2007 1559 1576
49. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
50. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
51. G.R. Foster, C. Hézode, J.P. Bronowicki, G. Carosi, O. Weiland, and L. Verlinden Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections Gastroenterology 141 2011 881 889
52. S. Kronenberger, and S. Zeuzem New developments in HCV therapy J Viral Hepat 19 Suppl. 1 2012 48 51
53. F.G. Hayden, A.D.M.E. Osterhaus, J.J. Treanor, D.M. Fleming, F.Y. Aoki, and K.G. Nicholson Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group N Engl J Med 337 1997 874 880
54. L.V. Gubareva, L. Kaiser, and F.G. Hayden Influenza virus neuraminidase inhibitors Lancet 355 2000 827 835
55. P.M. Colman Influenza virus neuraminidase: structure, antibodies, and inhibitors Protein Sci 3 1994 1687 1696
56. K.J. Cortez, and F. Maldarelli Clinical management of HIV drug resistance Viruses 3 2011 347 378
57. O. Turriziani, M. Andreoni, and G. Antonelli Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection Clin Microbiol Infect 16 2010 1518 1524
58. S. Palmer, F. Maldarelli, A. Wiegand, B. Bernstein, G.J. Hanna, and S.C. Brun Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy Proc Natl Acad Sci USA 105 2008 3879 3884
59. R.F. Siliciano What do we need to do to cure HIV infection Top HIV Med 18 2010 104 108
60. M. Coiras, M.R. López-Huertas, M. Pérez-Olmeda, and J. Alcamí Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs Nat Rev Microbiol 7 2009 798 812
61. D.D. Richman, D.M. Margolis, M. Delaney, W.C. Greene, D. Hazuda, and R.J. Pomerantz The challenge of finding a cure for HIV infection Science 323 2009 1304 1307
62. Centers for Disease Control and Prevention (CDC). Achievements in public health reduction in perinatal transmission of HIV infection - United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006;55:592-7.
63. J.S. Montaner, E. Wood, T. Kerr, V. Lima, R. Barrios, and K. Shannon Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes J Acquir Immune Defic Syndr 55 Suppl. 1 2010 S5 S9
64. R.M. Grant, J.R. Lama, P.L. Anderson, V. McMahan, A.Y. Liu, and L. Vargas Preexposure chemoprophylaxis for HIV prevention in men who have sex with men New Engl J Med 363 2010 2587 2599
65. M. Chaponda, and M. Pirmohamed Hypersensitivity reactions to HIV therapy Br J Clin Pharmacol 71 2011 659 671
66. V. Tozzi Pharmacogenetics of antiretrovirals Antiviral Res 85 2010 190 200
67. N.Y. Rakhmanina, and J.N. van den Anker Efavirenz in the therapy of HIV infection Expert Opin Drug Metab Toxicol 6 2010 95 103
68. B.Z. Wertheimer, K.A. Freedberg, R.P. Walensky, Y. Yazdanapah, and E. Losina Therapeutic drug monitoring in HIV treatment: a literature review HIV Clin Trials 7 2006 59 69
69. T. Kredo, J.S. Van der Walt, N. Siegfried, and K. Cohen Therapeutic drug monitoring of antiretrovirals for people with HIV Cochrane Database Syst Rev 2009 CD007268
70. E. Kindberg, A. Mickiene, C. Ax, B. Akerlind, S. Vene, and L. Lindquist A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis J Infect Dis 197 2008 266 269
71. J.K. Lim, and P.M. Murphy Chemokine control of West Nile virus infection Exp Cell Res 317 2011 569 574
72. P.M. Reeves, B. Bommarius, S. Lebeis, S. McNulty, J. Christensen, and A. Swimm Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases Nat Med 11 2005 731 739
73. H. Yang, S.K. Kim, M. Kim, P.A. Reche, T.J. Morehead, and I.K. Damon Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction J Clin Invest 115 2005 379 387
74. N. Holt, J. Wang, K. Kim, G. Friedman, X. Wang, and V. Taupin Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo Nat Biotechnol 28 2010 839 847
75. S.H. Rahman, M.L. Maeder, J.K. Joung, and T. Cathomen Zinc-finger nucleases for somatic gene therapy: the next frontier Hum Gene Ther 22 2011 925 933
76. + T cell resistance and enrichment Mol Ther 20 2012 849 859
77. H. Huthoff, and G.J. Towers Restriction of retroviral replication by APOBEC3G/F and TRIM5α Trends Microbiol 16 2008 612 619
78. R.L. Miller, T.C. Meng, and M.A. Tomai The antiviral activity of Toll-like receptor 7 and 7/8 agonists Drug News Perspect 21 2008 69 87
79. J.L. Fox Antivirals become a broader enterprise Nat Biotechnol 25 2007 1395 1402
80. W. Chen, and D.S. Dimitrov Monoclonal antibody-based candidate therapeutics against HIV type 1 AIDS Res Hum Retroviruses 28 2012 425 434
81. S.J. Zeller, and P. Kumar RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside Yale J Biol Med 84 2011 301 309
82. D. Ivacik, A. Ely, and P. Arbuthnot Countering hepatitis B virus infection using RNAi: how far are we from the clinic? Rev Med Virol 21 2011 383 396
83. L. Shen, S. Peterson, A.R. Sedaghat, M.A. McMahon, M. Callender, and H. Zhang Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs Nat Med 14 2008 762 766
84. B.L. Jilek, M. Zarr, M.E. Sampah, S.A. Rabi, C.K. Bullen, and J. Lai A quantitative basis for antiretroviral therapy for HIV-1 infection Nat Med 18 2012 446 451